About Nicholas Lydon
Born 1957. Nicholas Lydon is an American biochemist, chemist and researcher, known for Imatinib.
Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
Education Lydon was educated at Strathallan School near Perth, Scotland. He earned a Bachelor of Science degree in biochemistry from the University of Leeds, England in 1978 and received his PhD in biochemistry from the University of Dundee, Scotland in 1982.
Career In 1982, Lydon accepted a position with Schering-Plough based in France as Chargé de Récherche. Royal Society GlaxoSmithKline Prize and Lecture, 2014
Lydon's nomination for the Royal Society reads:
Don’t just read it —
keep it.
Full-length biographies made to live with: read them, listen on the way to work, watch them tonight.
- E-book
- Audio
- Video
Instant download · yours to keep · every purchase keeps this site free
Important facts
Contemporaries
People whose lives overlapped Nicholas Lydon's
Frequently asked questions
Who is Nicholas Lydon?
British biochemist
When was Nicholas Lydon born?
Nicholas Lydon was born on 27 February 1957.
What is Nicholas Lydon's occupation?
Nicholas Lydon is a biochemist, chemist and researcher.
What is Nicholas Lydon known for?
Nicholas Lydon is known for Imatinib.
What nationality is Nicholas Lydon?
Nicholas Lydon is American.
Sources & further reading
Cite this page
APA: Biography.guide. (2026). Nicholas Lydon. https://biography.guide/nicholas-lydon/
MLA: "Nicholas Lydon." Biography.guide, https://biography.guide/nicholas-lydon/.
Chicago: "Nicholas Lydon." Biography.guide. https://biography.guide/nicholas-lydon/.
Data last updated: 2026-09-20 · Spot an error? Report a correction.
Page generated 2026-09-27 05:30 UTC